MIGUEL ÁNGEL CALLEJA HERNÁNDEZ-rekin lankidetzan egindako argitalpenak (23)

2024

  1. Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study

    Journal of Clinical Medicine, Vol. 13, Núm. 4

2023

  1. Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 15

2021

  1. Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis

    Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47

  2. Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives

    Mutation Research - Reviews in Mutation Research, Vol. 788

  3. Impact of a risk-sharing agreement in rheumatoid arthritis in Spain

    Health Policy, Vol. 125, Núm. 3, pp. 335-340

2020

  1. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta

    Mutation Research - Reviews in Mutation Research, Vol. 785

2019

  1. Clinical pharmacy services: From cost-effectiveness analysis to a productivity indicators model

    European Journal of Hospital Pharmacy

2015

  1. Differences in cancer drug assessment between Spain and the United Kingdom

    European Journal of Cancer, Vol. 51, Núm. 13, pp. 1843-1852

  2. Pharmaceutical care in smoking cessation

    Patient Preference and Adherence, Vol. 9, pp. 209-215

2014

  1. Drug assessment by a Pharmacy and Therapeutics committee: From drug selection criteria to use in clinical practice

    Therapeutics and Clinical Risk Management, Vol. 10, Núm. 1, pp. 527-535

  2. Efectos de un programa de Atención Farmacéutica para pacientes con esclerosis múltiple sobre la adherencia al tratamiento inmunomodulador

    Ars pharmaceutica, Vol. 55, Núm. 1, pp. 37-44

  3. Results of the implementation of a pharmaceutical care programme for patients with multiple sclerosis

    European Journal of Hospital Pharmacy, Vol. 21, Núm. 4, pp. 248-250

2013

  1. Efectos de un programa de Atención Farmacéutica para pacientes con esclerosis múltiple sobre la adherencia al tratamiento inmunomodulador

    Ars pharmaceutica, Vol. 54, Núm. 4, pp. 1-8

  2. Effect of pharmacotherapy follow-up on treatment adherence and virologic and immune response in patients with human immunodeficiency virus

    Latin American Journal of Pharmacy, Vol. 32, Núm. 3, pp. 441-447

  3. Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma

    International Journal of Clinical Pharmacy, Vol. 35, Núm. 6, pp. 1105-1112

  4. Mejora del conocimiento sobre reacciones alérgicas cruzadas en dos grupos de medicamentos: b-lactámicos y AINEs

    Farmacia Hospitalaria, Vol. 37, Núm. 6, pp. 499-509

2012

  1. Adecuación de la profilaxis antimicrobiana perioperatoria en apendicitis

    Atencion Farmaceutica, Vol. 14, Núm. 4, pp. 245-250

  2. Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen

    Oncology Letters, Vol. 4, Núm. 5, pp. 1114-1118

  3. Estudio de adecuación a la ficha técnica de las prescripciones de trastuzumab en un hospital de tercer nivel

    Farmacia Hospitalaria, Vol. 36, Núm. 3, pp. 135-140

  4. La prescripción electrónica asistida: instrumento clave para la disminución de los problemas relacionados con los medicamentos en el hospital

    Pharmaceutical care España, Vol. 14, Núm. 6, pp. 229-237